Børge Sørvoll
Director of Finance/CFO at ARCTICZYMES TECHNOLOGIES ASA
Net worth: 259 593 $ as of 2024-03-30
Profile
Børge Sørvoll is currently the Chairman of Biotec BetaGlucans AS and the Chief Financial Officer of ArcticZymes Technologies ASA. Previously, he worked as the Managing Director & Chief Financial Officer of Troms Kraft Invest AS, the Chief Financial Officer of Front Exploration AS, and a Manager at Subsea 7 Norway AS.
He holds an MBA from the University of Wyoming.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-02-07 | 95,428 ( 0.19% ) | 259 593 $ | 2024-03-30 |
Børge Sørvoll active positions
| Companies | Position | Start |
|---|---|---|
| ARCTICZYMES TECHNOLOGIES ASA | Director of Finance/CFO | 2014-09-30 |
Biotec BetaGlucans AS
 Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The private company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million. | Chairman | - |
Former positions of Børge Sørvoll
| Companies | Position | End |
|---|---|---|
Front Exploration AS
 Front Exploration AS Contract DrillingIndustrial Services Front Exploration AS explores oil and gas and is ultimately controlled by the Government of Denmark. The private company is based in Tromsø, Norway. Front Exploration was acquired by Ørsted A/S on June 27, 2012. | Director of Finance/CFO | - |
Subsea 7 Norway AS
 Subsea 7 Norway AS Miscellaneous Commercial ServicesCommercial Services Part of Subsea 7 SA, Subsea 7 Norway AS is a Norwegian company that engages in general trading activities. The private company is based in Stavanger, Norway. The CEOs are John Evans, Monica Th. Bjørkmann. The company was founded in 1985. | Corporate Officer/Principal | - |
| Troms Kraft Invest AS | Chief Executive Officer | - |
Training of Børge Sørvoll
| University of Wyoming | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| ARCTICZYMES TECHNOLOGIES ASA | Health Technology |
| Private companies | 4 |
|---|---|
Front Exploration AS
Front Exploration AS Contract DrillingIndustrial Services Front Exploration AS explores oil and gas and is ultimately controlled by the Government of Denmark. The private company is based in Tromsø, Norway. Front Exploration was acquired by Ørsted A/S on June 27, 2012. | Industrial Services |
Subsea 7 Norway AS
Subsea 7 Norway AS Miscellaneous Commercial ServicesCommercial Services Part of Subsea 7 SA, Subsea 7 Norway AS is a Norwegian company that engages in general trading activities. The private company is based in Stavanger, Norway. The CEOs are John Evans, Monica Th. Bjørkmann. The company was founded in 1985. | Commercial Services |
| Troms Kraft Invest AS | |
Biotec BetaGlucans AS
Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The private company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million. | Health Technology |
- Stock Market
- Insiders
- Børge Sørvoll
